Beckman Coulter

The company's Life Sciences segment was up 17 percent year over year, while its Diagnostics business grew 8 percent.

The company's Diagnostics business was up 14 percent, while its Life Sciences business grew 13 percent. The firm also closed its $2 billion buy of IDT last week.

In Life Sciences, CEO Thomas Joyce noted a strong performance by Beckman Coulter, while in Diagnostics, he said Cepheid grew 25 percent year over year. 

The company said that EPS for next year is anticipated to be between $3.50 and $3.60. On an adjusted basis, EPS is expected in the range of $4.25 to $4.35. 

The firm beat the consensus Wall Street estimates on the top and bottom lines as the diagnostics segment saw revenues grow 20 percent year over year. 

Overall growth was driven by the company's diagnostics segment, which rose 11 percent, while life sciences improved 6 percent

The deal gives Beckman Coulter non-exclusive distribution rights in the US and Canada to the NGS library preparation kits for cell-free DNA in plasma.

The Beckman Coulter unit provides genomic sequencing solutions to healthcare businesses, governments, and academia around the world.

IncellDx's investigational molecular assay used to quantify HPV E6/E7 mRNA in single cells has been optimized to run on Beckman Coulter's CytoFlex flow cytometry system.